Author

Fabio Calabrò

h-index 7 View on Semantic Scholar

We have 3 of 30 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Pembrolizumab plus lenvatinib in first-line metastatic renal cell carcinoma: a single-institution experience and a case of severe treatment-related toxicity with durable tumour control

Background: Pembrolizumab plus lenvatinib is a standard first-line treatment for metastatic renal cell carcinoma (mRCC) based on the phase III CLEAR trial. Real- world data are needed to assess effectiveness and toxicity management in routine practice. We report a retrospective single-institution experience and a case...

A. Malgeri, G. Sirgiovanni, L. Cerbone et al. · Drugs in Context · 1 citation

Review Open access Oct 2026

Non-Conventional Histologies of Prostate Cancer: From Morphology to Biology-Driven Precision Oncology.

Non-conventional prostate cancer histologies represent a small but clinically significant subset characterised by aggressive behaviour, atypical biomarker profiles, and reduced dependence on androgen receptor signalling. Evidence indicates these histologies reflect dynamic biological states driven by genomic instabilit...

F. Flauto, G. Neola, Alessia Cimadamore et al. · The Oncologist · 0 citations

#explainable ai Sep 2026

Machine learning integrated explainable artificial intelligence in predicting toxicities of enfortumab vedotin in urothelial carcinoma: an exploratory study.

Preliminary, hypothesis-generating findings suggest ML may predict EV-related toxicities, but single train-test split, small event counts, and lack of external validation preclude clinical use.

K. Sridharan, Mattia Alberto Di Civita, G. Sivaramakrishnan et al. · Expert Review of Anticancer... · 0 citations